Clinical Trial

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Study acronym: Nafamostat
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Comparison nafamostat and low molecular weight heparin among dialysis patients
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-22; most recent amendment 2024-07-28.
Status change: Enrolling by Invitation → Recruiting 2024-07-28
Status change: Recruiting → Enrolling by Invitation 2023-08-17
Trial Details
NCT Number NCT05874674
Lead Sponsor Wonju Severance Christian Hospital
Conditions Dialysis; Complications, Bleeding
Enrollment 100 participants
Start Date 2023-12-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-30